Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aprea Therapeutics, Inc. - Common Stock
(NQ:
APRE
)
0.7960
+0.2060 (+34.92%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aprea Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
March 11, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
March 11, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
March 05, 2024
Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor)
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Inc. (NASDAQ: APRE) Making Surprising Moves in Thursday Session
April 06, 2023
Via
Investor Brand Network
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
February 06, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
January 30, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
January 04, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 09, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
A Look Into Healthcare Sector Value Stocks
↗
October 30, 2023
Via
Benzinga
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
October 24, 2023
Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ET
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
October 16, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
5 Value Stocks To Watch In The Healthcare Sector
↗
September 25, 2023
Via
Benzinga
5 Value Stocks To Watch In The Healthcare Sector
↗
September 04, 2023
Via
Benzinga
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
August 24, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
August 10, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
July 18, 2023
Via
Benzinga
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
June 14, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
↗
June 09, 2023
The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Aprea Therapeutics to Present at BIO International Convention
May 30, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
May 15, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
May 08, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
April 07, 2023
Via
Benzinga
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
March 30, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
↗
April 03, 2023
On Monday, 76 companies set new 52-week lows.
Via
Benzinga
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
March 16, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
↗
March 10, 2023
Via
Benzinga
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
March 07, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 01, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
February 27, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Why Aprea Therapeutics Shares Hit A New 52-Week Low Today
↗
February 23, 2023
Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading lower by 17.59% to $5.20 after the company announced pricing of a $5.5 million underwritten public offering of common stock. What Else?
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
